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ABSTRACT
As more people reaches advanced age, more people experience cognitive impairment and 
dementia. Dementia is a degenerative disease in which behavioural and psychological symptoms 
frequently occur, resulting in admissions to nursing homes (NHs), where the most common 
treatment has been medical treatment. The aim was to compare three rural Arctic NHs in 
Iceland in their use of psychiatric medication, type of dementia among residents, level of 
cognitive impairment and selected quality indicators, as well as considering national data, for 
the period 2016–2018. Data from the interRAI-MDS 2.0 evaluation were used. Residents with 
severe cognitive impairment used more antipsychotic medications, and residents with mild and 
severe cognitive impairment used more antidepressants than residents with no cognitive impair-
ment did. Diagnoses of Alzheimer’s Disease and Related Dementias (ADRD) are more common in 
the capital area and the national average than they are in the rural NHs. This indicates need for 
diagnostic assessments of ADRD to be conducted in rural areas. Benchmarking is beneficial for 
local and national regulatory bodies to find areas for improvement. The NHs did not have a lower 
quality of care compared with the whole country, but areas for improvement were identified. One 
of the NHs has already started this process.
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Introduction
Rural life differs from urban life in terms of the geogra-
phical conditions people experience, as well as the 
population’s educational level, income, and access to 
public transport [1,2] and specialist treatment [3]. 
Availability of specialist health services is important for 
older people because the number of people with such 
cognitive impairment as dementia is projected to 
increase, driven by population growth and demo-
graphic ageing [4]. Dementia is a degenerative disease 
in which behavioural and psychological symptoms fre-
quently occur [5,6]; these symptoms can include agita-
tion, aggression, wandering, depressive symptoms, and 
hallucination [5,7]. Dementia increases the rate of 
admission to nursing homes (NHs) [8,9]. Moreover, 
symptoms of dementia are more common and more 
severe in NHs than outside these institutions [6,10]. 
Management in the context of dementia symptoms 
usually involves medical treatment that focuses on 
complications, such as behavioural problems and 
depressive symptoms [11]. In NHs, psychotropic medi-
cations are often used to treat people with dementia, 
behaviour problems, and depression [12,13]. However, 
there is a general lack of evidence for the efficacy of 
using antipsychotic medications for elderly people suf-
fering from dementia [7,12], and regulatory bodies have 
issued warnings about using antipsychotics for this 
purpose [12].
Strategies to reduce the use of antipsychotics in 
NHs have resulted in moderately reducing the pre-
valence of these drugs in NHs [7]. Research has 
indicated that the location of NHs in rural areas is 
associated with less use of antipsychotic medications 
compared with NHs located in urban areas [13,14]. 
Contradicting results have however been published 
according to the size of nursing homes and use of 
antipsychotic for residents with dementia. In 
a review of 19 studies, Cioltan et al. [14] found 
that larger NHs in the USA used fewer antipsycho-
tics; in contrast, in a review covering 20 NHs with 
1,090 residents in the Netherlands, Kleijer et al. [13] 
revealed that smaller NHs were less likely to admin-
ister antipsychotic medications to residents.
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The Icelandic population is ageing, and projections 
show the highest expected increase in the oldest old 
[15], with a greater proportion of people ≥ 65 years in 
rural areas compared with the capital area [15]. Such 
a population shift will increase the prevalence of 
dementia and the need for NHs in rural Iceland.
The aim of this study was to compare residents in 
three Arctic NHs in the period of 2016–2018 in terms of 
their level of cognitive impairment, use of psychiatric 
medications over the last 7 days, types of dementia, 
and selected quality indicators (QIs). A further aim was 
to compare their use of psychotropic medications in the 
last 7 days according to the residents’ level of cognitive 
impairment. Additionally, to compare data from the 
three small NHs with data from all nursing homes in 
Iceland and data from nursing homes in the capital area 
of Iceland over the same period.
Materials and methods
Setting and participants
Around 2,600 people live in 73 NHs and long-term 
facilities in Iceland [16], in this study NH is referred to 
as an institutional setting. In 2019, the total popula-
tion of people ≥ 65 years of age was 47,684, which is 
around 13.6% of the Icelandic population [15]. The 
eastern part of Iceland is the rural area that is furthest 
away from the Icelandic capital area, where slightly 
under two-thirds of the total Icelandic population 
lives (see Figure 1). The eastern part of Iceland is 
sparsely populated, with a total population around 
10,000, or about 3.2% of the total population of 
Iceland, in an area that is around 16,000 m2 [17]. 
The inhabitants live on farms and in small fishing 
villages, where the largest village has around 2,800 
inhabitants. The area has one healthcare institution, 
an umbrella institution consisting of one small hospi-
tal serving as an emergency department for the area, 
seven primary healthcare centres, and four primary 
health clinics open for a few hours each week. As 
a part of the umbrella healthcare institution, there are 
three small NHs in different villages, and those are 
the settings for our study. In addition, there are three 
small NHs in the area run by the local municipalities. 
The Icelandic health service, including NHs, is publicly 
funded.
Most residents in our three NHs had been 
admitted to the NHs from the local area, and most 
were from the same postcode as their NH. However, 
there were some differences: In the largest NH (NH 
A), the proportion of residents from other postal 
codes was 22%; in NH B, it was 31%; and in NH C, 
it was 41%. Although the three NHs are part of the 
same umbrella institution, the staff are different in 
each NH because more registered nurses work at 
NH C compared with the other two NHs. Only one 
out of the three NHs received an annual visit from 
a geriatrician at that time.
The data for this study were from the Resident 
Assessment Instrument Minimum Data Set 2.0 instru-
ment (interRAI-MDS 2.0), designed for use in nursing 
homes. Since 1996, it has been mandatory for Icelandic 
NHs to assess residents with the interRAI-MDS 2.0 
instrument at admission and since 2003 at least three 
times a year. Results from interRAI-MDS 2.0 are used as 
a basis for nursing home reimbursement [18]. The 
interRAI-MDS 2.0 assessment used in our study was 
the newest assessment for each resident over the 
research period 2016–2018.
Figure 1. Map of Iceland: Box illustrates East Iceland, where the study was conducted; circle demarcates the capital area.
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Design
Descriptive, retrospective study of data from the 
interRAI-MDS 2.0. The instrument consists of five parts: 
a) the Minimum Data Set 2.0 (MDS 2.0); b) Quality 
Indicators (QIs), c) interRAI scales, d) Resident 
Assessment Protocols, and e) Resource Utilisation 
Groups. The interRAI-MDS 2.0 was initially designed to 
rate the functioning and healthcare needs of NH resi-
dents although instruments for other settings have 
since been developed [19]. The assessment is con-
ducted by nurses who have received standardised train-
ing in using the interRAI-MDS 2.0 and is based on 
observations, clinical documentation, and interviews 
with residents and their family members. The interRAI- 
MDS 2.0 assessment was originally designed as 
a clinical tool to improve care, but it has also been 
used internationally for research purposes and is con-
sidered over all a reliable and valid instrument [19]. 
However, other studies have pointed out that some 
data elements in the interRAI-MDS 2.0 has shown 
poor inter-rater reliability [20], which can affect the 
outcome of scales and QI’s. The MDS 2.0 for NHs is 
the documentation part of the interRAI with about 
350 clinical data elements.
Selected variables from interRAI-MDS 2.0 were used; 
these comprised background variables, such as age, 
gender and NH A, B, or C; psychotropic medications; 
and type of dementia. Psychotropic medications 
included in the analyses were antipsychotics (N05A), 
anxiolytics (N05B), antidepressants (N06A), and hypno-
tics and sedatives (N05C). Residents receiving any type 
of these medications the last 7 days before assessment 
were considered to be using the medications.
The Cognitive Performance Scale (CPS) was used to 
measure residents’ cognitive performance; it rates 
impairment from 0, indicating that the resident is cog-
nitively intact, to 6, indicating severe cognitive impair-
ment. The scale is a part of the interRAI-MDS 2.0 and 
the outcome is calculated using selected variables from 
the instrument such as comatose status, short-term 
memory, cognitive skills for daily decision making, and 
self-performance in eating. The scale correlates moder-
ately well with the Mini-Mental State Examination 
(MMSE; r = 0.65) [21].
QIs were calculated using one or more variables from 
the interRAI-MDS 2.0 assessment of each resident. They 
represent certain treatments the resident either has or 
has not received or conditions s/he is presenting. 
A high proportion of residents presenting a certain QI 
in a nursing home indicates low quality of care [22]. 
Research has shown that some of the QI’s show more 
sensitivity in measuring quality of care [23] and other 
QI’s have been found unsuitable for public reporting of 
nursing home quality [24]. The Directorate of Health in 
Iceland uses the interRAI-MDS 2.0 QI for quality inspec-
tions in the nursing homes among other quality mea-
sures. The following QIs were used in this study: 
behavioural symptoms affecting others; use of nine or 
more different medications; antipsychotic drug use in 
the absence of psychotic and related conditions; anti-
anxiety or hypnotic drug use; hypnotic drug use on 
more than 2 days in the past week; prevalence of 
depression; and little or no activity. The Directorate of 
Health provided information about selected variables 
and interRAI-MDS 2.0 QIs for the whole country and 
the capital area in Iceland for the research period.
Statistical analysis
Data were analysed using descriptive statistics (mean, 
standard deviation, percentages), as well as inferential 
statistics. Residents were compared according to cogni-
tive status measured with the CPS scale, rated as no 
cognitive impairment (CPS: 0–1), mild cognitive impair-
ment (CPS: 2–3), or severe cognitive impairment (CPS: 
4–6) [20]. Residents were also compared according to 
the use of psychotropic medications, with possible 
responses of “yes” or “no.” In the comparison, we used 
univariate analysis of variance (ANOVA) and chi-squared 
tests. Binary logistic regression was employed to esti-
mate the association between psychotropic medication 
use and cognitive impairment, the association among 
cognitive impairment and diagnoses of anxiety and 
hallucination, and the association between QIs of beha-
viour problems and depressive symptoms of cognitive 
impairment compared to residents with no cognitive 
impairment. A significant statistical difference was set at 
p ≤ 0.05.
Ethical considerations
The Icelandic National Bioethics Committee 
(VSN–18–121) and Data Protection Authority of the 
Icelandic Ministry of Justice approved the research.
Results
Over three years, 156 residents were assessed in the 
three NHs. Table 1 shows that NH A was the biggest, 
with 51.9% of all the study’s residents. The age range 
was 34–99 years, and around 17% were younger than 
70 years. The mean age for all residents was 80.8 (±9.5) 
years, with a median of 84 years, and 92 (58%) were 
women. Residents with no cognitive impairment were 
57 or 36.5%. No association was found between 
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cognitive impairment and gender or age of the resident 
or NHs (A, B, or C). Antidepressants were the most used 
psychotropic medication, and they were used by 66 
(42.3%) of all 156 residents. Antipsychotics were used 
by only five residents in NH A, and antipsychotics were 
used less there than in the other two NHs. The average 
number of medications used was 9.1 medications 
per day. One resident did not use any prescribed med-
ications, but 11 (7.1%) residents used more than 17 
medications per day. No association was found among 
how many prescribed medications the residents used 
and cognitive status, gender, or NH (A, B, or C). The QI 
of “behavioral symptoms affecting others” was less 
common in NHs A and B compared with NH C, and in 
the largest NH (NH A), the QI “antipsychotic drug use in 
the absence of psychotic and related conditions” was 
only active for three residents.
Considering psychotropic medication use for the last 
7 days according to residents’ cognitive impairment, we 
found an association between cognitive impairment 
and the use of antipsychotics, as well as antidepressant 
medications. Residents with severe cognitive impair-
ment used more antipsychotic medications, whereas 
residents with mild and severe cognitive impairment 
used more antidepressants than residents with no cog-
nitive impairment did. In the last 7 days, 50% of resi-
dents with severe cognitive impairment used 
antipsychotic medications, and they were over three 
times more likely to use antipsychotics (odds ratio 
[OR] 3.41 [95% confidence interval (CI) 1.32–8.82], 
p = 0.011) compared with residents without cognitive 
impairment or exhibiting a mild form of cognitive 
impairment. They were also three times more likely to 
be prescribed antidepressants than those with absent 
or mild cognitive impairment (OR 3.32 [95% CI 1.4–-
7.70], p = 0.005). There was no difference in the pre-
scription of hypnotic sedatives (N05C) and anxiolytics 
(N05B) according to cognitive status. Residents with 
cognitive impairment were more often diagnosed with 
anxiety and delusions (health condition), and residents 
with severe cognitive impairment were three times 
more likely to be diagnosed with anxiety compared 
with those without cognitive impairment (OR 2.97 
[95% CI 1.28–6.89], p = 0.011). The OR of the QI of 
“behavioral problems affecting others” among residents 
with severe cognitive impairment was 28-fold higher 
compared with those with no impairment (OR 28.125 
[95% CI 7.51–105.40], p = 0.001). The QI of “prevalence 
Table 1. Mean age, age range, gender, cognitive impairment, and psychotropic medication use in the last 7 days in the three 
nursing homes (N = 156). Number (n) and percentage (%) according to each nursing home.
NH A (n = 81; 52%) NH B (n = 26; 17%) NH C (n = 49; 31%) p-value
Mean age, year (sf) 81.3 (10.517) 83.7(7.244) 78.4(10.766) 0.083*
Age groups, n (%)
≤70 years 11 (13.6) 2 (12.5) 14 (28.6)
71–84 years 32 (39.5) 9 (34.6) 17 (34.7)
84–99 years 38 (46.9) 15 (57.7) 18 (36.7)
Gender 0.223**
Female 51 (63.0) 17 (65.4) 24 (49.0)
Male 30 (37.0) 9 (34.6) 25 (51.0)
Cognitive impairment
No cognitive impairment 25 (30.9) 14 (53.8) 18 (36.7)
Mild cognitive impairment 36 (44.4) 5 (19.2) 17 (34.7) 0.062**
Severe cognitive impairment 20 (24.7) 7 (26.9) 14 (28.6) 0.885**
Medication use last 7 days
Antipsychotics (N05A) 5 (6.2) 9 (34.6) 18 (36.7) 0.001**
Sedatives (N05B) 26 (32.1) 7 (26.9) 12 (24.5) 0.632**
Antidepressants (N06A) 28 (34.6) 13 (50.0) 25 (51.0) 0.126**
Hypnotics (N05C) 35 (43.2) 11 (42.3) 14 (28.6) 0.228**
Medical diagnosis
Delusions (health condition) 12 (14.8) 4 (15.4) 19 (38.8) 0.001**
Anxiety 44 (54.3) 8 (30.8) 14 (28.6) 0.017**
Alzheimer disease 10 (12.4) 4 (15.4) 10 (20.4) 0.071**
Dementia other than Alzheimer 30 (37.0) 3 (11.5) 13 (26.5) 0.042**
Quality indicators
Behavioural symptoms affecting others 19 (23.5) 5 (19.2) 16 (32.7) 0.009**
Use of nine or more different medications 40 (49.4) 10 (38.5) 32 (65.3) 0.116**
Antipsychotic drug use in the absence of psychotic and related conditions 3 (3.7) 8 (30.8) 12 (24.5) 0.001**
Antianxiety or hypnotic drug use 42 (51.9) 12 (46.2) 19 (38.8) 0.002**
Hypnotic drug use more than 2 days in past week 33 (40.7) 11 (42.3) 13 (26.5) 0.331**
Depression prevalence 23 (28.4) 9 (34.6) 19 (38.8) 0.658**
Little or no activity 13 (16.1) 9 (34.6) 14 (28.6) 0.198**
* Univariate ANOVA 
** Chi-square test 
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of depression” increased with more cognitive impair-
ment, and in residents with severe cognitive impair-
ment, the odds were almost 7-fold (OR 6.82 [95% CI 
2.66–17.48], p = 0.001), compared to residents without 
cognitive impairment.
Table 2 shows data from the Directorate of Health for 
the period of 2016–2018. The mean age of residents was 
84.4 years, and 61.7% were women (N = 5,242 RAI-MDS 
2.0 assessments). The two medical diagnoses of 
Alzheimer disease versus Dementia other than 
Alzheimer disease, were more common in the capital 
area and the national average than in our three NHs. 
The data also show that the use of antipsychotics 
(N05A) was lower in NH A than the national average or 
the average in the capital area, but the two other NHs 
used more antipsychotics. It is also noteworthy that, in 
NH A, only three residents used antipsychotic drugs in 
the absence of psychotic and related conditions over the 
three years that were studied; moreover, the occurrence 
of behavioural problems towards others was similar in NH 
A compared with the other two NHs, the national aver-
age, and the average in the capital area. In addition, the 
QI “little or no activity” was lower in NH A than in the two 
other NHs and the national average.
Discussion
This study contributes significantly to the sparse knowl-
edge about the use of psychiatric medication in small 
rural NHs in Arctic areas. It is noteworthy that the great-
est difference between the three NHs was in the use of 
antipsychotics (NO5A; p < 0.001). The biggest NH in our 
study, or NH A, had a minimal usage of antipsychotics 
(6.2%), which would be considered a good outcome. 
Contradictory results have been reported regarding the 
use of antipsychotics according to the size of NHs, but 
in their review, Cioltan et al. [14] claimed that larger 
NHs in the USA used fewer antipsychotics compared 
with smaller ones. Here, the QI of “antipsychotic drug 
use in absence of psychotic and related conditions” was 
active among 14.7% of residents in the three NHs. 
However, there was a difference among the three NHs 
in terms of this QI: Fewer residents in NH A (3.7%) 
exhibited this QI compared with NH B (30.8%) and NH 
C (24.5%), and the average for Iceland was 23.9%. This 
demonstrates the importance of analysing data from 
each NH for improvements. In addition, NH A used 
fewer antipsychotics compared with the other two 
NHs (34.6–36.7%), which used more antipsychotics 
than the average in the capital area (27.2%), as well as 
the average for Iceland (23.2%). A nationwide study [25] 
from Icelandic NHs from the period 1999–2009 
demonstrated this QI to be active in 25–30% of all 
cases, which is comparable to our results.
Researchers have reported prescription of strong 
psychotropic drugs in NHs to be around 30% [13,26]. 
A literature review from NHs in 12 Western European 
countries [27], looking at prescription of antipsychotics 
(37 studies) and antidepressants (27 studies) during the 
years 2004–2015, found the pooled prevalence of use 
of antipsychotics to be 27%. It should be noted that, 
even though antipsychotics were used less in NH A, the 
QI of “behavior symptoms affecting others” was not 
more common there compared to the other two NHs, 
and the percentage was similar as in the capital area 
and Iceland. Warnings about adverse events associated 
with the use of strong psychotropics for older people 
with dementia and behavioural problems have been 
discussed over the years [27] and have pointed out 
that non-pharmacological treatments have shown posi-
tive effects in the treatment of behavioural problems 
[11,28]. Our study showed the OR to be more than 
threefold that at severe cognitive impairment increased 
the risk of use of psychotropic medication (antipsycho-
tics; N05A) and antidepressants (N06A) in the last 7 days 
compared with residents without severe cognitive 
impairment. In a Canadian study, the risk of being pre-
scribed antipsychotic medications for residents 
(N = 47,768) newly admitted to NHs was largest if the 
resident had both cognitive impairment and demen-
tia [29].
The medical diagnoses of Alzheimer disease are 
more prevalent in the capital area (40.6%) and nation-
ally in Iceland (31.1%) than in our three NHs. One 
explanation for this could be that, in rural Iceland, 
there are few specialists in geriatric medicine who can 
diagnose ADRD specifically [3]. This issue is concerning 
if it means people in rural areas do not get the right 
medical diagnosis of Alzheimer disease in time because 
a delayed diagnosis can affect their opportunities to 
receive treatment for the disease [30]. However, most 
people with dementia do not receive a diagnosis, or if 
they do, this happens late in the disease course [4]. In 
a study of Norwegian NHs [31], 83.8% out of 696 resi-
dents were diagnosed with Alzheimer disease but only 
55.9% of those with Alzheimer were registered with 
medical diagnoses in their medical records. It is 
known that medical diagnosis is not always documen-
ted in medical records [32], but medical diagnosis is the 
foundation for appropriate treatment.
For people with ADRD, care should be evidence 
based, and the prescription of antipsychotic medication 
should be based on professional assessment and that 
the resident is really in need of the medication. 
A nationwide study in the USA [26] including 1,257 
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NHs, where data (N = 66,181) were collected through 
interRAI evaluation, reported that around 29% 
(n = 4,818) of residents received at least one strong 
antipsychotic medication and 32% (1545) had no iden-
tified indication for use of the medication; other studies 
have supported these findings [33].
What in the rural areas may explain the differences 
among our three NHs? Although the three NHs are 
a part of the same healthcare institution, there are 
multiple elements that are different in their practice. 
For example, access to medical staff was different; some 
of the NHs did not have the same doctor evaluating 
residents from week to week, and thus, residents may 
not have had stability in their treatment. Only one of 
the three NHs received annual consultations and visits 
from a geriatrician. The combination of staff was also 
different in the NHs, including nurses, nurse assistants, 
and helpers with no professional education. It is known 
that staff’s attitudes affect how psychotic and related 
conditions are handled [14] and the challenges the 
nursing staff may experience due to those symp-
toms [10].
The eastern part of Iceland has few inhabitants, and 
people in the local areas often know each other and the 
relatives of NH residents. This can affect how the local 
staff approach residents. A difference was evident 
between the NHs in how many residents moved from 
other parts of the country to stay in the three NHs. In 
NH C, over 40% of the residents were not from the local 
fishing village, whereas in NH A, around 20% were not 
from the local village. People with ADRD are often 
sensitive to the familiarity of the environment and 
local residents might even have had some previous 
contact with the staff, which can affect both the beha-
viour of the staff and the residents´.
It is important that small and larger NHs use interRAI- 
MDS 2.0 results to evaluate and improve the quality of 
the service they provide. They need to compare QI 
thresholds to identify the need for improvement for the 
NH as a whole, as well as for each resident in the NH, to 
be able to make improvements based on the QIs. One NH 
in this study (NH C) successfully used the results to work 
on improvements emphasising QIs concerning the use of 
psycholeptic medications (NO5A–B and NO5 C). In that 
process, outcomes from individual QIs were used, as well 
as the outcome for the whole nursing home.
The strength of the study is that almost all residents 
in the three NHs were assessed with interRAI-MDS 2.0 
during the study period. It can also be considered 
a strength that benchmarking was conducted between 
our NHs and national data, giving valuable information 
for the three NHs. There are however some weaknesses 
concerning the data that need to be taken into 
consideration when interpreting the findings of this 
study. Although the interRAI-MDS 2.0 instrument [34] 
and the scales [19] are a valuable resource for research 
some data elements of the instrument have poor inter- 
rater reliability [20] and therefore caution must be used 
when interpreting findings. There is also a need for 
further research on the reliability and validity of the 
interRAI-MDS 2.0 QI as mixed results have been pub-
lished and the suitability of the QI for comparisons 
questioned [35]. It is also a limitation of the study that 
at the NHs are small with few residents in each NH and 
therefore the outcome is more sensitive to results of 
one resident and it limited how many variables could 
be included into the regression models. As the study 
was cross-sectional, causality cannot be inferred. In 
addition, the data used were collected for clinical use, 
not research. However, the registered nurses responsi-
ble for collecting the data were qualified to carry out 
the assessment.
Conclusion
This study contributes to the sparse knowledge about 
how small rural Arctic NHs use psychiatric medication, 
as well as to information about prevalence of demen-
tia and psychiatric symptoms in the NHs. Small rural 
NHs are understudied, and our NHs are located in 
sparsely populated areas. That the diagnoses of 
ADRD were more common in the capital area than 
in the three NHs stresses the importance of distribut-
ing healthcare services into rural areas to increase the 
accessibility for vulnerable groups, such as residents 
living in NHs. Benchmarking is beneficial for local and 
national regulatory bodies to find areas for improve-
ment. We demonstrated that our NHs did not have 
a lower quality of care compared to the whole coun-
try, but there were areas for improvements, and one 
of the NHs had already started that process, to ana-
lyse the use of psycholeptic medications. Indicating 
how outcomes from individual interRAI-MDS 2.0 QIs, 
as well as the outcome for the whole nursing home 
can be used to improve quality of care in NHs.
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